Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.
Robert L. Ferris
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Amgen; Bristol-Myers Squibb
Neil D. Gross
Research Funding - Takara Bio; Theradex
John J. Nemunaitis
No relevant relationships to disclose
Robert Hans Ingemar Andtbacka
No relevant relationships to disclose
Athanassios Argiris
No relevant relationships to disclose
James Ohr
Honoraria - Bayer/Onyx; Bristol-Myers Squibb; Genentech
John T. Vetto
Honoraria - Merck
Neil N. Senzer
No relevant relationships to disclose
Cindi Bedell
No relevant relationships to disclose
Richard S. Ungerleider
Consultant or Advisory Role - Theradex
Maki Tanaka
Employment or Leadership Position - Takara Bio
Yukihiro Nishiyama
Consultant or Advisory Role - Takara Bio